author-photo

Ernest S. Smith

University of Rochester

67

Papers

525

Citations

Citation Trend

Filter By

Papers (46) Sort By

Journal Conference Others

SEMA4D upregulation signals neuronal stress and triggers reactive transformation of astrocytes

2021
Show All
- Source
- Cite
- Save
Citations (0)
Integrated Biomarker Study of Pepinemab in Combination with Nivolumab or Ipilimumab to Evaluate Immune Cell Composition of TME in Patients with Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

2020 International Journal of Radiation Oncology Biology Physics
Show All
- Source
- Cite
- Save
Citations (0)
726 SRF114 is a fully human, CCR8 selective IgG1 antibody that induces destruction of tumor Tregs through ADCC

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Abstract CT191: Interim results from CLASSICAL-Lung, phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC

2020 Tumor Biology
Show All
- Source
- Cite
- Save
Citations (0)
Evidence that semaphorin 4D is upregulated in neurons in Huntington’s and Alzheimer’s diseases: Effects of a SEMA4D blocking antibody on FDG‐PET in a clinical trial, and treatment rationale for its use in AD: Human/Human trials: Other

2020 Alzheimers & Dementia
Show All
- Source
- Cite
- Save
Citations (0)
Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function

2019 Cancer immunology research
Show All
- Source
- Cite
- Save
Citations (19)
Preliminary results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract PR10: Reprogramming myeloid cells in TME with pepinemab, first-in-class semaphorin 4D MAb, enhances combination immunotherapy

2019 Cancer immunology research
Show All
- Source
- Cite
- Save
Citations (0)
VX15 ANTI-SEMAPHORIN 4D ANTIBODY (PEPINEMAB) INCREASES FDG-PET SIGNAL AND IS A POTENTIAL TREATMENT FOR ALZHEIMER’S DISEASE

2019 Alzheimers & Dementia
Show All
- Source
- Cite
- Save
Citations (0)